CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 268,500 shares, an increase of 241.6% from the February 13th total of 78,600 shares. Based on an average daily trading volume, of 576,500 shares, the short-interest ratio is currently 0.5 days. Approximately 9.9% of the company’s shares are sold short.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Wealthfront Advisers LLC bought a new stake in shares of CNS Pharmaceuticals during the 4th quarter valued at $26,000. Integrated Wealth Concepts LLC purchased a new stake in CNS Pharmaceuticals in the fourth quarter worth about $30,000. Connective Capital Management LLC bought a new position in shares of CNS Pharmaceuticals during the fourth quarter valued at approximately $34,000. XTX Topco Ltd bought a new stake in shares of CNS Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, Citadel Advisors LLC bought a new position in CNS Pharmaceuticals during the 4th quarter valued at approximately $39,000. 14.02% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Alliance Global Partners upgraded CNS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 24th.

CNS Pharmaceuticals Price Performance

CNSP traded up $0.31 on Friday, hitting $3.02. The company had a trading volume of 160,600 shares, compared to its average volume of 731,701. CNS Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $1,100.00. The stock has a fifty day simple moving average of $4.51 and a 200-day simple moving average of $5.71. The firm has a market capitalization of $3.47 million, a P/E ratio of -0.04 and a beta of 2.65.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.